A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, Jennings GT, Bachmann MF.
Ambühl PM, et al. Among authors: sabat r.
J Hypertens. 2007 Jan;25(1):63-72. doi: 10.1097/HJH.0b013e32800ff5d6.
J Hypertens. 2007.
PMID: 17143175
Clinical Trial.